Ident. | Authors (with country if any) | Title |
---|
000028 |
Sylvia Navailles [France] ; Lea Milan [France] ; Hanane Khalki [France] ; Giuseppe Di Giovanni [Royaume-Uni, Malte] ; Mélanie Lagiere [France] ; Philippe De Deurwaerdere [France] | Noradrenergic Terminals Regulate L-DOPA-derived Dopamine Extracellular Levels in a Region-dependent Manner in Parkinsonian Rats |
000032 |
N. Daviaud [France] ; E. Garbayo [France, Espagne] ; N. Lautram [France] ; F. Franconi [France] ; L. Lemaire [France] ; M. Perez-Pinzon [États-Unis] ; C. N. Montero-Menei [France] | MODELING NIGROSTRIATAL DEGENERATION IN ORGANOTYPIC CULTURES, A NEW EX VIVO MODEL OF PARKINSON'S DISEASE |
000033 |
G. Drui [France] ; S. Carnicella [France] ; C. Carcenac [France] ; M. Favier [France] ; A. Bertrand [France] ; S. Boulet [France] ; M. Savasta [France] | Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease |
000040 |
M. Morales [États-Unis] ; D. H. Root [États-Unis] | GLUTAMATE NEURONS WITHIN THE MIDBRAIN DOPAMINE REGIONS |
000046 |
J. Mendoza [France] ; E. Challet [France] | CIRCADIAN INSIGHTS INTO DOPAMINE MECHANISMS |
000057 |
V. Phe [France] ; R. Caremel [France] ; S. Bart [France] ; E. Castel-Lacanal [France] ; M. De Seze [France] ; F. Duchene [France] ; A. Even [France] ; X. Game [France] ; M. Loubat [France] ; M. C. Scheiber Nogueira [France] ; G. Karsenty [France] | Troubles vésicosphinctériens des syndromes parkinsoniens: une revue du comité de neuro-urologie de l'Association française d'urologie |
000078 |
Julie Peron [Suisse] ; Sascha Frühholz [Suisse] ; Marc Verin [France] ; Didier Grandjean [Suisse] | Subthalamic nucleus: A key structure for emotional component synchronization in humans |
000091 |
P. De Deurwaerdère [France] ; M. Lagière [France] ; M. Bosc [France] ; S. Navailles [France] | Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology |
000097 |
P. M. Abedi [France, Maroc] ; C. Delaville [France] ; P. De Deurwaerdere [France] ; W. Benjelloun [Maroc] ; A. Benazzouz [France] | INTRAPALLIDAL ADMINISTRATION OF 6-HYDROXYDOPAMINE MIMICS IN LARGE PART THE ELECTROPHYSIOLOGICAL AND BEHAVIORAL CONSEQUENCES OF MAJOR DOPAMINE DEPLETION IN THE RAT |
000108 |
A. Laux-Biehlmann [France] ; J. Mouheiche [France] ; J. Veriepe [France] ; Y. Goumon [France] | ENDOGENOUS MORPHINE AND ITS METABOLITES IN MAMMALS: HISTORY, SYNTHESIS, LOCALIZATION AND PERSPECTIVES |
000113 |
M. Jaber [France] ; M. Benoit-Marand [France] ; L. Prestoz [France] ; A. Gaillard [France] | Cell transplantation in the damaged adult brain |
000122 |
T. Dondaine [France] ; J. Peron [France, Suisse] | Émotion et noyaux gris centraux (I): que peut nous apprendre la maladie de Parkinson ? |
000155 |
Etienne C. Hirsch [France] | Futures pistes thérapeutiques médicamenteuses pour la maladie de Parkinson |
000171 |
P. De Deurwaerdere [France] ; S. Navailles [France] | What can we expect from the serotonergic side of L-DOPA? |
000174 |
Laurie Mondillon [France] ; Martial Mermillod [France] ; Serban C. Musca [France] ; Isabelle Rieu [France] ; Tiphaine Vidal [France] ; Patrick Chambres [France] ; Catherine Auxiette [France] ; Helene Dalens [France] ; Louise Marie Coulangeon [France] ; Isabelle Jalenques [France] ; Jean-Jacques Lemaire [France] ; Miguel Ulla [France] ; Philippe Derost [France] ; Ana Marques [France] ; Franck Durif [France] | The combined effect of subthalamic nuclei deep brain stimulation and L-dopa increases emotion recognition in Parkinson's disease |
000179 |
Eugenie Lhommee [France] ; Hélène Klinger [France] ; Stéphane Thobois [France] ; Emmanuelle Sch Mitt [France] ; Claire Ardouin [France] ; Amélie Bichon [France] ; Andrea Kistner [France] ; Valérie Fraix [France] ; JING XIE [France] ; Magaly Aya Kombo [France] ; Stephan Chabardes [France] ; Eric Seigneuret [France] ; Alim-Louis Benabid [France] ; Patrick Mertens [France] ; Gustavo Polo [France] ; Sebastien Carnicella [France] ; Jean-Louis Quesada [France] ; Jean-Luc Bosson [France] ; Emmanuel Broussolle [France] ; Pierre Pollak [France] ; Paul Krack [France] | Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours |
000196 |
Nicolas Aznavour [France] ; Christophe Cendres-Bozzi [France] ; Laetitia Lemoine [France] ; Colette Buda [France] ; Jean-Pierre Sastre [France] ; Zoïa Mincheva [France] ; Luc Zimmer [France] ; Jian-Sheng Lin [France] | MPTP Animal Model of Parkinsonism: Dopamine Cell Death or Only Tyrosine Hydroxylase Impairment? - A Study Using PET Imaging, Autoradiography, and Immunohistochemistry in the Cat |
000211 |
Eloi Magnin [France] ; Marie Vidailhet [France] ; Ilham Ryff [France] ; Sabrina Ferreira [France] ; Pierre Labauge [France] ; Lucien Rumbach [France] | Fronto-striatal dysfunction in type 3 familial cortical myoclonic tremor epilepsy occurring during aging |
000220 |
Asha Kishore [Inde] ; Thomas Joseph [Inde] ; Balu Velayudhan [Inde] ; Traian Popa [France] ; Sabine Meunier [France] | Early, severe and bilateral loss of LTP and LTD-like plasticity in motor cortex (M1) in de novo Parkinson's disease |
000222 |
C. Delaville [France] ; S. Navailles [France] ; A. Benazzouz [France] | EFFECTS OF NORADRENALINE AND SEROTONIN DEPLETIONS ON THE NEURONAL ACTIVITY OF GLOBUS PALLIDUS AND SUBSTANTIA NIGRA PARS RETICULATA IN EXPERIMENTAL PARKINSONISM |
000232 |
Sophie Schumm [France] ; Claude Sebban [France] ; Charles Cohen-Salmon [France] ; Jacques Callebert [France] ; Jean-Marie Launay [France] ; Jean-Louis Golmard [France] ; Lydie Boussicault [France] ; Isabelle Petropoulos [France] ; Audrey Hild [France] ; Estelle Rousselet [France] ; Annick Prigent [France] ; Bertrand Friguet [France] ; Jean Mariani [France] ; Etienne C. Hirsch [France] | Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine |
000234 |
Asha Kishore [Inde] ; Traian Popa [France] ; Balu Velayudhan [Inde] ; Thomas Joseph [Inde] ; Ammu Balachandran [Inde] ; Sabine Meunier [France] | Acute dopamine boost has a negative effect on plasticity of the primary motor cortex in advanced Parkinson's disease |
000264 |
Alexandre Baratta [France] ; Hervé Javelot [France] ; Luisa Weiner [France] | Maladie de Parkinson et violences sexuelles: Implication des traitements dopaminergiques |
000267 |
Sophie Bayard [France] ; Valérie Cochen De Cock [France] ; Yves Dauvillers [France] | Le syndrome de dysrégulation dopaminergique dans la maladie de Parkinson et le syndrome des jambes sans repos |
000272 |
L. Bindler [France] ; M. Anheim [France] ; C. Tranchant [France] ; P. Vidailhet [France] | La créativité du patient parkinsonien |
000306 |
Siobhan Vicente [France] ; Julie Peron [France] ; Isabelle Biseul [France] ; Sophie Ory [France] ; Pierre Philippot [Belgique] ; Sophie Drapier [France] ; Dominique Drapier [France] ; Marc Verin [France] | Subjective emotional experience at different stages of Parkinson's disease |
000311 |
Elaine Del-Bel [France] ; Fernando Eduardo Padovan-Neto [France] ; Rita Raisman-Vozarl [France] ; Marcio Lazzarini [France] | Role of Nitric Oxide in Motor Control: Implications for Parkinson's Disease Pathophysiology and Treatment |
000314 |
Sylvia Navailles [France] ; Philippe De Deurwaerdere [France] | Presynaptic control of serotonin on striatal dopamine function |
000324 |
Jennifer T. Coull [France] ; Ruey-Kuang Cheng [États-Unis] ; Warren H. Meck [États-Unis] | Neuroanatomical and Neurochemical Substrates of Timing |
000346 |
Giselle Charron [France] ; Evelyne Doudnikoff [France] ; Alexis Laux [France] ; Amandine Berthet [France] ; Gregory Porras [France] ; Marie-Hélène Canron [France] ; Pedro Barroso-Chinea [France] ; QIN LI [République populaire de Chine] ; CHUAN QIN [République populaire de Chine] ; Marika Nosten-Bertrand [France] ; Bruno Giros [France] ; François Delalande [France] ; Alain Van Dorsselaer [France] ; Anne Vital [France] ; Yannick Goumon [France] ; Erwan Bezard [France, République populaire de Chine] | Endogenous morphine-like compound immunoreactivity increases in parkinsonism |
000360 |
M. Carta [Suède, Italie] ; E. Bezard [France] | CONTRIBUTION OF PRE-SYNAPTIC MECHANISMS TO L-DOPA-INDUCED DYSKINESIA |
000390 |
Léon Tremblay [France] | Où en sommes-nous sur la physiopathologie de la maladie de Parkinson ? |
000397 |
S. Thobois [France] ; C. Ardouin [France] ; E. Schmitt [France] ; E. Lhommee [France] ; H. Klinger [France] ; J. Xie [France] ; C. Lagrange [France] ; A. Kistner [France] ; M. Aya Kombo [France] ; V. Fleury [France] ; A. Poisson [France] ; V. Fraix [France] ; E. Broussolle [France] ; P. Pollak [France] ; P. Krack [France] | Maladie de Parkinson: de la physiopathologie des troubles psychiques à la maîtrise du traitement dopaminergique |
000405 |
Emmanuelle Apartis [France] ; Stéphane Melik-Parsadaniantz [France] ; Alice Guyon [France] ; Patrick Kitabgi [France] ; William Rostene [France] | Les chimiokines, de nouveaux acteurs dans le système dopaminergique |
000465 |
Kwamivi Dzahini [France] ; Christine Dentresangle [France] ; Marion Le Cavorsin [France] ; Anne Bertrand [France] ; Isabelle Detraz [France] ; Marc Savasta [France] ; Vincent Leviel [France] | Pre-synaptic glutamate-induced activation of DA release in the striatum after partial nigral lesion |
000484 |
Dawn M. Eagle [Royaume-Uni] ; Christelle Baunez [France] | Is there an inhibitory-response-control system in the rat? Evidence from anatomical and pharmacological studies of behavioral inhibition |
000488 |
Stephane Besnard [France] ; Michael Decressac [France] ; Pierre Denise [France] | In-vivo deep brain recordings of intranigral grafted cells in a mouse model of Parkinson's disease |
000490 |
Peter Redgrave [Royaume-Uni] ; Manuel Rodriguez [Espagne] ; Yoland Smith [États-Unis] ; Maria C. Rodriguez-Oroz [Espagne] ; Stephane Lehericy [France] ; Hagai Bergman [Israël] ; Yves Agid [France] ; Mahlon R. Delong [États-Unis] ; Jose A. Obeso [Espagne] | Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease |
000501 |
David Devos [France] ; L. Defebvre [France] ; R. Bordet [France] | Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease |
000507 |
A. Faure [France] ; P. Leblanc-Veyrac [France] ; N. El Massioui [France] | DOPAMINE AGONISTS INCREASE PERSEVERATIVE INSTRUMENTAL RESPONSES BUT DO NOT RESTORE HABIT FORMATION IN A RAT MODEL OF PARKINSONISM |
000530 |
C. Ardouin [France] ; I. Chereau [France] ; P.-M. Llorca [France] ; E. Lhommee [France] ; F. Durif [France] ; P. Pollak [France] ; P. Krack [France] | Évaluation des troubles comportementaux hyper- et hypodopaminergiques dans la maladie de Parkinson |
000563 |
L. Defebvre [France] | Douleur et maladie de Parkinson |
000588 |
Serge Guerreiro [France] ; Aurélie Ponceau [France] ; Damien Toulorge [France] ; Elodie Martin [France] ; Daniel Alvarez-Fischer [France] ; Etienne C. Hirsch [France] ; Patrick P. Michel [France] | Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization |
000614 |
R. Bouali-Benazzouz [France] ; C. H. Tai [France, Taïwan] ; J. Chetrit [France] ; A. Benazzouz [France] | INTRAPALLIDAL INJECTION OF 6-HYDROXYDOPAMINE INDUCED CHANGES IN DOPAMINE INNERVATION AND NEURONAL ACTIVITY OF GLOBUS PALLIDUS |
000619 |
Anne-Sophie Rolland [France] ; Dominique Tande [France] ; Maria-Trinidad Herrero [Espagne] ; Maria-Rosario Luquin [Espagne] ; Marianne Vazquez-Claverie [Espagne] ; Carine Karachi [France] ; Etienne C. Hirsch [France] ; Chantal Francois [France] | Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication |
000624 |
Pauline Delaveau [France] ; Pilar Salgado-Pineda [France, Espagne] ; Tatiana Witjas [France] ; Joëlle Micallef-Roll [France] ; Eric Fakra [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] | Dopaminergic Modulation of Amygdala Activity During Emotion Recognition in Patients With Parkinson Disease |
000635 |
Gabriel Robert [France] ; Dominique Drapier [France] ; Marc Verin [France] ; Bruno Millet [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] | Cognitive Impulsivity in Parkinson's Disease Patients: Assessment and Pathophysiology |
000641 |
Julie Peron [France] ; Siobhan Vicente [France] ; Emmanuelle Leray [France] ; Sophie Drapier [France] ; Dominique Drapier [France] ; Renaud Cohen [France] ; Isabelle Biseul [France] ; Tiphaine Rouaud [France] ; Florence Le Jeune [France] ; Paul Sauleau [France] ; Marc Verin [France] | Are dcpaminergic pathways involved in theory of mind? A study in Parkinson's disease |
000651 |
M. Guthrie [États-Unis, France] ; C. E. Myers [États-Unis] ; M. A. Gluck [États-Unis] | A neurocomputational model of tonic and phasic dopamine in action selection : A comparison with cognitive deficits in Parkinson's disease |
000670 |
M. Borg [France] ; C. Bayreuther [France] | Syndrome de dysrégulation dopaminergique dans la maladie de Parkinson |
000674 |
C. Monaca [France] | Somnolence et syndromes parkinsoniens |
000680 |
Pierre Cesaro [France] | Neuroprotection et maladie de Parkinson |
000685 |
André Galinowski [France] ; May Ghossoub [France] ; Thomas Weber [France] | Les troubles anxieux dans la maladie de Parkinson |
000695 |
J.-M. Gerard [France] | Initiation du traitement de la maladie de Parkinson et son adaptation en fonction de l'évolution |
000703 |
S. Dethy [France] ; A.-S. Hambye [France] | Apport de la scintigraphie par 123I.FP.CIT (DaTSCANTM) au diagnostic différentiel des troubles du mouvement |
000707 |
Laura Flinn [Royaume-Uni] ; Sandrine Bretaud [France] ; Christine Lo [Royaume-Uni] ; Phillip W. Ingham [Royaume-Uni] ; Oliver Bandmann [Royaume-Uni] | Zebrafish as a new animal model for movement disorders |
000722 |
A. Carmona [France, Espagne] ; G. Deves [France] ; R. Ortega [France] | Quantitative micro-analysis of metal ions in subcellular compartments of cultured dopaminergic cells by combination of three ion beam techniques |
000724 |
Grégory Porras [France] ; Erwan Bezard [France] | Preclinical development of gene therapy for Parkinson's disease : Gene therapy for parkinson's disease |
000730 |
Gaëlle Bouchez [France] ; Luc Sensebe [France] ; Patrick Vourc'H [France] ; Lucette Garreau [France] ; Sylvie Bodard [France] ; Angélique Rico [France] ; Denis Guilloteau [France] ; Pierre Charbord [France] ; Jean-Claude Besnard [France] ; Sylvie Chalon [France] | Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease |
000735 |
Patrick Emond [France] ; Denis Guilloteau [France] ; Sylvie Chalon [France] | PE21 : A Radiopharmaceutical for In vivo Exploration of the Dopamine Transporter |
000736 |
Luca Ferraro [Italie] ; Maria Cristina Tomasini [Italie] ; Roberta Mazza [Italie] ; Kjell Fuxe [Suède] ; Jacqueline Fournier [France] ; Sergio Tanganelli [Italie] ; Tiziana Antonelli [Italie] | Neurotensin receptors as modulators of glutamatergic transmission |
000737 |
Dieter Scheller [Allemagne] ; Christine Stichel-Gunkel [Allemagne] ; Hermann Lübbert [Allemagne] ; Gregory Porras [France] ; Paula Ravenscroft [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Erwan Bezard [France, Royaume-Uni] | Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease |
000742 |
Daniel Alvarez-Fischer [France] ; Serge Guerreiro [France] ; Stephane Hunot [France] ; Francoise Saurini [France] ; Marc Marien [France] ; Pierre Sokoloff [France] ; Etienne C. Hirsch [France] ; Andreas Hartmann [France] ; Patrick P. Michel [France] | Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid |
000745 |
Carine Chassain [France] ; Guy Bielicki [France] ; Elodie Durand [France] ; Stéphane Lolignier [France] ; Fatma Essafi [Tunisie] ; Amidou Traore [France] ; Franck Durif [France] | Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse |
000760 |
Nathalie Thiriet [France] ; Lahouari Amar [France] ; Xauier Toussay [France] ; Virginie Lardeux [France] ; Bruce Ladenheim [États-Unis] ; Kevin G. Becker [États-Unis] ; Jean Lud Cadet [États-Unis] ; Marcello Solinas [France] ; Mohamed Jaber [France] | Environmental enrichment during adolescence regulates gene expression in the striatum of mice |
000774 |
E. Y. Pioli [France] ; W. Meissner [France] ; R. Sohr [Allemagne] ; C. E. Gross [France] ; E. Bezard [France] ; B. H. Bioulac [France] | DIFFERENTIAL BEHAVIORAL EFFECTS OF PARTIAL BILATERAL LESIONS OF VENTRAL TEGMENTAL AREA OR SUBSTANTIA NIGRA PARS COMPACTA IN RATS |
000775 |
Dieter Scheller [Allemagne] ; Nick Dürrafiller [France] ; Paul Moser [France] ; Roger D. Porsolt [France] | Continuous stimulation of dopaminergic receptors by rotigotine does not interfere with the sleep-wake cycle in the rat |
000777 |
A. Marighetto [France] ; S. Valerio [France] ; J. N. Philippin [France] ; V. Bertaina-Anglade [France] ; C. Drieu La Rochelle [France] ; R. Jaffard [France] ; P. Morain [France] | Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents |
000781 |
Daniel Alvarez-Fischer [Allemagne] ; Carmen Henze [Allemagne] ; Corinna Strenzke [Allemagne] ; Jan Westrich [Allemagne] ; Boris Ferger [Allemagne] ; Günter U. Höglinger [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Andreas Hartmann [Allemagne, France] | Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice |
000785 |
Dominique Guehl [France] ; Pierre Burbaud [France] ; Christian Lorenzi [France] ; Christophe Ramos [France] ; Bernard Bioulac [France] ; Catherine Semal [France] ; Laurent Demany [France] | Auditory temporal processing in Parkinson's disease |
000791 |
Virginie Czernecki [France] ; Michael Schüpbach [France, Suisse] ; Sadek Yaici [France] ; Richard Levy [France] ; Eric Bardinet [France] ; Jérome Yelnik [France] ; Bruno Dubois [France] ; Yves Agid [France] | Apathy Following Subthalamic Stimulation in Parkinson Disease : A Dopamine Responsive Symptom |
000795 |
Margarete Zanardo Gomes [Brésil] ; Rita Raisman-Vozari [France] ; Elaine A. Del Bel [Brésil] | A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway |
000843 |
Charlotte Laloux [France] ; Philippe Derambure [France] ; Jean-Marie Jacquesson [France] ; Régis Bordet [France] ; Alain Destée [France] ; Christelle Monaca [France] | The effects of serotoninergic, noradrenergic, cholinergic and dopaminergic drugs on vigilance states in MPTP-treated mice |
000850 |
Elvira De Leonibus [Italie] ; Tiziana Pascucci [Italie] ; Sebastien Lopez [France] ; Alberto Oliverio [Italie] ; Marianne Amalric [France] ; Andrea Mele [Italie] | Spatial deficits in a mouse model of Parkinson disease |
000851 |
Elvira De Leonibus [Italie] ; Tiziana Pascucci [Italie] ; Sebastien Lopez [France] ; Alberto Oliverio [Italie] ; Marianne Amalric [France] ; Andrea Mele [Italie] | Spatial deficits in a mouse model of Parkinson disease |
000856 |
Dieter Scheller [Allemagne] ; PIU CHAN [République populaire de Chine] ; QIN LI [Royaume-Uni] ; TAO WU [République populaire de Chine] ; RENLING ZHANG [République populaire de Chine] ; LE GUAN [République populaire de Chine] ; Paula Ravenscroft [Royaume-Uni] ; Celine Guigoni [France] ; Alan R. Crossman [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Erwan Bezard [France] | Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease |
000857 |
Patrick P. Michel [France] ; Daniel Alvarez-Fischer [France] ; Serge Guerreiro [France] ; Audrey Hild [France] ; Andreas Hartmann [France] ; Etienne C. Hirsch [France] | Role of activity-dependent mechanisms in the control of dopaminergic neuron survival |
000861 |
Robert A. Hauser [États-Unis] ; Laurence Salin [France] ; Nolwenn Juhel [France] ; Victor L. Konyago [États-Unis] | Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (Tesofensine) in early parkinson's disease |
000896 |
S. Breit [France, Allemagne] ; R. Bouali-Benazzouz [France] ; R. C. Popa [Allemagne] ; T. Gasser [Allemagne] ; A. L. Benabid [France] ; A. Benazzouz [France] | Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat |
000897 |
M. Berk [Australie] ; S. Dodd [Australie] ; M. Kauer-Sant'Anna [Canada] ; G. S. Malhi [Australie] ; M. Bourin [France] ; F. Kapczinski [Brésil] ; T. Norman [Australie] | Dopamine dysregulation syndrome : implications for a dopamine hypothesis of bipolar disorder |
000924 |
Richard Levy [France] ; Bernard Pillon [France] | Troubles cognitifs non démentiels de la maladie de Parkinson |
000984 |
Dominique Drapier [France] ; Sophie Drapier [France] ; Paul Sauleau [France] ; Pascal Derkinderen [France] ; Philippe Damier [France] ; Herve Allain [France] ; Marc Verin [France] ; Bruno Millet [France] | Pathological gambling secondary to dopaminergic therapy in Parkinson's disease |
000985 |
Claire Ardouin [France] ; Valerie Voon [Canada] ; Yulia Worbe [France] ; Nehman Abouazar [France] ; Virginie Czernecki [France] ; Hassan Hosseini [France] ; Antoine Pelissolo [France] ; Elena Moro [Canada] ; Eugénie Lhommee [France] ; Anthony E. Lang [Canada] ; Yves Agid [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] ; Luc Mallet [France] ; Paul Krack [France] | Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation |
000990 |
Dominique Tande [France] ; Günter Höglinger [Allemagne] ; Thomas Debeir [France] ; Nils Freundlieb [Allemagne] ; Etienne C. Hirsch [France] ; Chantal Francois [France] | New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis |
000A11 |
Yuri Bozzi [Italie] ; Emiliana Borrelli [France] | Dopamine in neurotoxicity and neuroprotection : what do D2 receptors have to do with it? |
000A35 |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
000A57 |
France Haour [France] | Mécanismes de l'effet placebo et du conditionnement : Données neurobiologiques chez l'homme et l'animal |
000B07 |
D. Guilloteau [France] ; S. Chalon [France] | PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders : Capabilities of PET and SPECT in pre-clinical and clinical research |
000B21 |
Carmen Henze [France] ; Thomas Lescot [France] ; Sabine Traver [France] ; Bénédicte Salthun-Lassalle [France] ; Etienne C. Hirsch [France] ; Patrick P. Michel [France] ; Andreas Hartmann [France] | Granulocyte colony-stimulating factor is not protective against selective dopaminergic cell death in vitro |
000B40 |
Philippe Remy [France, Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; Andrew Lees [Royaume-Uni] ; Nora Turjanski [Royaume-Uni] ; David Brooks [Royaume-Uni] | Depression in Parkinson's disease : loss of dopamine and noradrenaline innervation in the limbic system |
000B46 |
I. J. Bohr [Royaume-Uni] ; M. A. Ray [Royaume-Uni] ; J. M. Mcintosh [États-Unis] ; S. Chalon [France] ; D. Guilloteau [France] ; I. G. Mckeith [Royaume-Uni] ; R. H. Perry [Royaume-Uni] ; F. Clementi [Italie] ; E. K. Perry [Royaume-Uni] ; J. A. Court [Royaume-Uni] ; M. A. Piggott [Royaume-Uni] | Cholinergic nicotinic receptor involvement in movement disorders associated with Lewy body diseases : An autoradiography study using [125I]α-conotoxinMII in the striatum and thalamus |
000B50 |
Carine Chassain [France] ; Guy Bielicki [France] ; Jean-Pierre Donnat [France] ; Jean-Pierre Renou [France] ; Alain Eschalier [France] ; Franck Durif [France] | Cerebral glutamate metabolism in Parkinson's disease : an in vivo dynamic 13C NMS study in the rat |
000B56 |
Tatiana Witjas [France] ; Christelle Baunez [France] ; Jean Marc Henry [France] ; Marie Delfini [France] ; Jean Regis [France] ; André Ali Cherif [France] ; Jean Claude Peragut [France] ; Jean Philippe Azulay [France] | Addiction in Parkinson's disease : Impact of subthalamic nucleus deep brain stimulation |
000B98 |
Hélène Legros [France] ; Marie-George Dingeval [France] ; Francois Janin [France] ; Jean Costentin [France] ; Jean-Jacques Bonnet [France] | Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: Relationships with 3,4-dihydroxyphenylacetaldehyde formation |
000C02 |
Jean-Antoine Girault [France] ; Paul Greengard [États-Unis] | The neurobiology of dopamine signaling |
000C12 |
M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada] | Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate |
000C14 |
Paula Ravenscroft [Royaume-Uni] ; Sylvie Chalon [France] ; Jonathan M. Brotchie [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] | Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia |
000C15 |
Vincent Paille [France] ; Philippe Brachet [France] ; Philippe Damier [France] | Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease |
000C18 |
Howard T. J. Mount [Canada] ; Jean-Claude Martel [France] ; Paul Fluit [Canada] ; YINGJI WU [Canada] ; Eleanor Gallo-Hendrikx [Canada] ; Cristina Cosi [France] ; Marc R. Marien [France] | Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia |
000C32 |
Jill L. Smith [France] ; Jeong-Sun Ju [France] ; Bithika M. Saha [France] ; Brad A. Racette [France, États-Unis] ; Jonathan S. Fisher [France] | Levodopa with carbidopa diminishes glycogen concentration, glycogen synthase activity, and insulin-stimulated glucose transport in rat skeletal muscle |
000C36 |
Jean-Jacques Bacci [France] ; Philippe Kachidian [France] ; Lydia Kerkerian-Le Goff [France] ; Pascal Salin [France] | Intralaminar thalamic nuclei lesions: Widespread impact on dopamine denervation-mediated cellular defects in the rat basal ganglia |
000C42 |
Wassilios Meissner [Allemagne, France] ; Daniel Harnack [Allemagne] ; Nora Hoessle [Allemagne] ; Erwan Bezard [France] ; Christine Winter [Allemagne] ; Rudolf Morgenstern [Allemagne] ; Andreas Kupsch [Allemagne] | High frequency stimulation of the entopeduncular nucleus has no effect on striatal dopaminergic transmission |
000C46 |
Carlos Barcia [Espagne] ; Angel Sanchez Bahillo [Espagne] ; Emiliano Fernandez-Villalba [Espagne] ; Victor Bautista [Espagne] ; Maximo Poza Y. Poza [Espagne] ; Andrés Fernandez-Barreiro [Espagne] ; Etienne C. Hirsch [France] ; Maria-Trinidad Herrero [Espagne] | Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure |
000C52 |
Makoto Naoi [Japon] ; Wakako Maruyama [Japon] ; Georgy M. Nagy [Hongrie] | Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: Occurrence, metabolism and function in human brains |
000C60 |
N. Hamaue [Japon] ; M. Minami [Japon] ; M. Terado [Japon] ; M. Hirafuji [Japon] ; T. Endo [Japon] ; M. Machida [Japon] ; T. Hiroshige [Japon] ; A. Ogata [Japon] ; K. Tashiro [Japon] ; H. Saito [Japon] ; S. H. Parvez [France] | Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus |
000D34 |
Valérie Cochen [France] ; Maria-Joao Ribeiro [France] ; Jean-Paul Nguyen [France] ; Jean-Marc Gurruchaga [France] ; Gabriel Villafane [France] ; Christian Loc'H [France] ; Gilles Defer [France] ; Yves Samson [France] ; Marc Peschanski [France] ; Philippe Hantraye [France] ; Pierre Cesaro [France] ; Philippe Remy [France] | Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue |
000D42 |
Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni] | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study |
000D48 |
Erwan Bezard [France] ; Christian E. Gross [France] ; Jonathan M. Brotchie [Canada] | Presymptomatic compensation in Parkinson's disease is not dopamine-mediated |
000D49 |
Roberto Maggio [Italie] ; Marco Scarselli [Italie] ; Francesca Novi [Italie] ; Mark J. Millan [France] ; Giovanni U. Corsini [Italie] | Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole |
000D51 |
Christian E. Gross [France] ; Paula Ravenscroft [France] ; Sandra Dovero [France] ; Mohamed Jaber [France] ; Bernard Bioulac [France] ; Erwan Bezard [France] | Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice |
000D66 |
Larissa Takser [France] ; Donna Mergler [Canada] ; Georgette Hellier [France] ; Josiane Sahuquillo [France] ; Guy Huel [France] | Manganese, monoamine metabolite levels at birth, and child psychomotor development |
000D71 |
Mauro Maccarrone [Italie] ; Paolo Gubellini [France, Italie] ; Monica Bari [Italie] ; Barbara Picconi [Italie] ; Natalia Battista [Italie] ; Diego Centonze [Italie] ; Giorgio Bernardi [Italie] ; Alessandro Finazzi-Agro [Italie] ; Paolo Calabresi [Italie] | Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism |
000D81 |
G. Fenelon [France] ; S. Gimenez-Roldan [Espagne] ; J. L. Montastruc [France] ; F. Bermejo [Espagne] ; F. Durif [France] ; I. Bourdeix [France] ; J.-J. Pere [Espagne] ; L. Galiano [Suisse] ; J. Schadrack | Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study |
000D90 |
Günter U. Höglinger [France] ; Géraldine Carrard [France] ; Patrick P. Michel [France] ; Fadia Medja [France] ; Anne Lombes [France] ; Merle Ruberg [France] ; Bertrand Friguet [France] ; Etienne C. Hirsch [France] | Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease |
000E04 |
Olivier Guillin [France] ; Nathalie Griffon [France] ; Erwan Bezard [France] ; Ludovic Leriche [France] ; Jorge Diaz [France] ; Christian Gross [France] ; Pierre Sokoloff [France] | Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease |
000E46 |
A. Nieoullon [France] ; M. Amalric [France] | Les récepteurs dopaminergiques : aspects structuraux et implications fonctionnelles |
000E51 |
André Galinowski [France] ; Marie-Laure Paillere-Martinot [France] | La stimulation magnétique transcrânienne répétée : Vers un nouvel outil thérapeutique en psychiatrie : Les avancées scientifiques en psychiatrie |
000E79 |
P. Sokoloff [France] ; J.-C. Schwartz [France] | The dopamine D3 receptor and its implication in neuropsychiatric disorders and their treatments |
000E86 |
Chara Malapani [États-Unis] ; Bernard Deweer [France] ; John Gibbon [États-Unis] | Separating storage from retrieval dysfunction of temporal memory in Parkinson's disease |
000E89 |
Estelle Rousselet [France] ; Jacques Callebert [France] ; Karine Parain [France] ; Chantal Joubert [France] ; Stéphane Hunot [France] ; Andreas Hartmann [France] ; Claude Jacque [France] ; Fernando Perez-Diaz [France] ; Charles Cohen-Salmon [France] ; Jean-Marie Launay [France] ; Etienne C. Hirsch [France] | Role of TNF-α receptors in mice intoxicated with the parkinsonian toxin MPTP |
000E93 |
Stéphanie Barc [France] ; Guylène Page [France] ; Laurence Barrier [France] ; Lucette Garreau [France] ; Denis Guilloteau [France] ; Bernard Fauconneau [France] ; Sylvie Chalon [France] | Relevance of different striatal markers in assessment of the MPP+-induced dopaminergic nigrostriatal injury in rat |
000E95 |
T. Breidert [France] ; J. Callebert [France] ; M. T. Heneka [Allemagne] ; G. Landreth [États-Unis] ; J. M. Launay [France] ; E. C. Hirsch [France] | Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease |
000E97 |
Stéphanie Barc [France] ; Guylène Page [France] ; Laurence Barrier [France] ; Francois Huguet [France] ; Bernard Fauconneau [France] | Progressive alteration of neuronal dopamine transporter activity in a rat injured by an intranigral injection of MPP+ |
000F16 |
V. Czernecki [France] ; B. Pillon [France] ; J. L. Houeto [France] ; J. B. Pochon [France] ; R. Levy [France] ; B. Dubois [France] | Motivation, reward, and Parkinson's disease: influence of dopatherapy |
000F23 |
Yoko Hirata [Japon] | Manganese-induced apoptosis in PC12 cells |
000F44 |
Aïcha Douhou [France] ; Thomas Debeir [France] ; Mario Gustavo Murer [Argentine] ; Louis Do [France] ; Noëlle Dufour [France] ; Véronique Blanchard [France] ; Saliha Moussaoui [France] ; Georg Andrees Bohme [France] ; Yves Agid [France] ; Rita Raisman-Vozari [France] | Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice |
000F45 |
A. D. Smith [États-Unis] ; M. Amalric [France] ; G. F. Koob [États-Unis] ; M. J. Zigmond [États-Unis] | Effect of bilateral 6-hydroxydopamine lesions of the medial forebrain bundle on reaction time |
000F66 |
Bernard Bruguerolle [France] ; Nicolas Simon [France] | Biologic rhythms and Parkinson's disease: A chronopharmacologic approach to considering fluctuations in function |
000F69 |
Stéphane Le Crom [France] ; Delphine Prou [France] ; Philippe Vernier [France] | Autocrine activation of adenosine A1 receptors blocks D1A but not D1B dopamine receptor desensitization |
001001 |
O. Rascol [France] ; J. Ferreira [France, Portugal] ; J.-L. Montastruc [France] | Pharmacologie: Somnolence diurne anormale, « attaques de sommeil » et médicaments antiparkinsoniens |
001016 |
Gilles Fenelon [France] | Démons et déments: hallucinations et maladies neurodégénératives |
001024 |
Zhong-Ge Ni [France] ; Rabia Bouali-Benazzouz [France] ; Dong-Ming Gao [République populaire de Chine] ; Alim-Louis Benabid [France] ; Abdelhamid Benazzouz [France] | Time-course of changes in firing rates and firing patterns of subthalamic nucleus neuronal activity after 6-OHDA-induced dopamine depletion in rats |
001033 |
C. Prunier [France] ; F. Tranquart [France] ; J. P. Cottier [France] ; B. Giraudeau [France] ; S. Chalon [France] ; D. Guilloteau [France] ; B. De Toffol [France] ; F. Chossat [France] ; A. Autret [France] ; J. C. Besnard [France] ; J. L. Baulieu [France] | Quantitative analysis of striatal dopamine D2 receptors with 123I-iodolisuride SPECT in degenerative extrapyramidal diseases |
001049 |
Laurent Groc [États-Unis, France] ; Laurent Bezin [États-Unis, France] ; Jane A. Foster [États-Unis] ; HAO JIANG [États-Unis] ; Tangella S. Jackson [États-Unis] ; Dinah Weissmann [France] ; Robert A. Levine [États-Unis] | Lipid peroxidation-mediated oxidative stress and dopamine neuronal apoptosis in the substantia nigra during development |
001054 |
Laurent Pezard [France] ; Robert Jech [République tchèque] ; Evzen Ruzicka [République tchèque] | Investigation of non-linear properties of multichannel EEG in the early stages of Parkinson's disease |
001062 |
Christine Dentresangle [France] ; Marion Le Cavorsin [France] ; Marc Savasta [France] ; Vincent Leviel [France] | Increased extracellular DA and normal evoked DA release in the rat striatum after a partial lesion of the substantia nigra |
001063 |
Stéphanie Barc [France] ; Guylène Page [France] ; Laurence Barrier [France] ; Alain Piriou [France] ; Bernard Fauconneau [France] | Impairment of the neuronal dopamine transporter activity in MPP+-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors |
001093 |
Thomas Poyot [France] ; Francoise Conde [France] ; Marie-Claude Gregoire [France] ; Vincent Frouin [France] ; Christine Coulon [France] ; Chantal Fuseau [France] ; Francoise Hinnen [France] ; Frédéric Dolle [France] ; Philippe Hantraye [France] ; Michel Bottlaender [France] | Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: Comparison with 6-[18f]Fluoro-L-Dopa |
001094 |
Stéphanie Barc [France] ; Guylène Page [France] ; Bernard Fauconneau [France] ; Laurence Barrier [France] ; Francois Huguet [France] | A new in vitro approach for investigating the MPTP effect on DA uptake |
001095 |
David Blum [Belgique, France] ; Sakina Torch [France] ; Marie-France Nissou [France] ; Jean-Marc Verna [France] | 6-hydroxydopamine-induced nuclear factor-kappab activation in PC12 cells |
001140 |
Pierre Sokoloff [France] | Le père de la dopamine |
001146 |
Bertrand Bloch [France] | La dopamine dans tous ses états |
001169 |
N. Fournet [France] ; O. Moreaud [France] ; J. L. Roulin [France] ; B. Naegele [France] ; J. Pellat [France] | Working memory functioning in medicated Parkinson's disease patients and the effect of withdrawal of dopaminergic medication |
001175 |
A. Boireau [France] ; P. Dubedat [France] ; F. Bordier [France] ; A. Imperato [France] ; S. Moussaoui [France] | The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP+ accumulation |
001177 |
M. G. Murer [France, Argentine] ; G. Dziewczapolski [Argentine] ; P. Salin [France] ; M. Vila [France] ; K. Y. Tseng [Argentine] ; M. Ruberg [France] ; M. Rubinstein [Argentine] ; M. A. Kelly [États-Unis] ; D. K. Grandy [États-Unis] ; M. J. Low [États-Unis] ; E. Hirsch [France] ; R. Raisman-Vozari [France] ; O. Gershanik [Argentine] | The indirect basal ganglia pathway in dopamine D2 receptor-deficient mice |
001205 |
A.-M. Bonnet [France] | Involvement of non-dopaminergic pathways in Parkinson's disease : Pathophysiology and therapeutic implications |
001215 |
R. J. M. Swaans [Pays-Bas] ; P. Rondot [Pays-Bas] ; W. O. Renier [France] ; L. P. W. J. Van Den Heuvel [Pays-Bas] ; G. C. H. Steenbergen-Spanjers [Pays-Bas] ; R. A. Wevers [Pays-Bas] | Four novel mutations in the tyrosine hydroxylase gene in patients with infantile parkinsonism |
001231 |
C. Warren Olanow [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] | Continuous dopamine-receptor stimulation in early Parkinson's disease |
001254 |
| ETUDE DES CARACTERISTIQUES PHARMACOLOGIQUES ET DU RÔLE DES AUTO ET DES HETERORECEPTEURS 5-HT1B DANS LE CONTRÔLE DE L'ACTIVITE DOPAMINERGIQUE DU STRIATUM |
001262 |
L. Defebvre [France] ; MARCHANDISE ; VIDAILHET ; TOUCHON ; CHACCOUR ; TRANQUART ; SAMSON ; MELKI | Traitement médical de la maladie de Parkinson. Discussion |
001265 |
J.-L. Baulieu [France] ; C. Prunier [France] ; F. Tranquart [France] ; D. Guilloteau [France] ; VAN DER BORGHT ; DEFEBVRE ; ZANCA ; VIDAILHET ; GRASSET ; PAILLARD ; SAMSON ; BAULAC ; STEINLING ; CLANET ; TOUCHON | Résultats cliniques de la temp de la neurotransmission en pathologie extra-pyramidale. Discussion. Table ronde |
001289 |
G. Mercier [France] ; J. C. Turpin [France] ; G. Lucotte [France] | Variable number tandem repeat dopamine transporter gene polymorphism and Parkinson's disease : no association found |
001294 |
P. Damier [France, États-Unis] ; E. C. Hirsch [France] ; Yves Agid [France] ; A. M. Graybiel [États-Unis] | The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease |
001295 |
P. Damier [France, États-Unis] ; E. C. Hirsch [France] ; Yves Agid [France] ; A. M. Graybiel [États-Unis] | The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D28K immunohistochemistry |
001306 |
R. M. Marie [France] ; L. Barre [France] ; B. Dupuy [France] ; F. Viader [France] ; G. Defer [France] ; J. C. Baron [France] | Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease |
001316 |
S. Bourgoin [France] ; S. Rostaing-Rigattieri [France] ; J.-P. Nguyen [France] ; E. Berberich [France] ; P. Duvaldestin [France] ; C.-M. Fattaccini [France] ; M. Hamon [France] ; F. Cesselin [France] | Opposite changes in dopamine metabolites and met-enkephalin levels in the ventricular CSF of patients subjected to thalamic electrical stimulation |
001368 |
E. Bezard [France] ; C. E. Gross [France] ; M.-C. Fournier [France] ; S. Dovero [France] ; B. Bloch [France] ; M. Jaber [France] | Absence of MPTP-lnduced neuronal death in mice lacking the dopamine transporter |
001371 |
H. Bagheri [France] ; C. Damase-Michel [France] ; M. Lapeyre-Mestre [France] ; S. Cismondo [France] ; D. O'Connell [Irlande (pays)] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France] | A study of salivary secretion in Parkinson's disease |
001372 |
J. A. Aguirre [Espagne] ; A. Cintra [Suède] ; J. Hillion [Suède] ; J. A. Narvaez [Espagne] ; A. Jansson [Suède] ; T. Antonelli [Italie] ; L. Ferraro [Italie] ; F. A. Rambert [France] ; K. Fuxe [Suède] | A stereological study on the neuroprotective actions of acute Modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse |
001400 |
M. Jaber [États-Unis] ; B. Bloch [États-Unis] ; M. G. Caron [France] ; B. Giros [France] | Conséquences comportementales, cellulaires et moléculaires de l'inactivation du gène du transporteur de la dopamine : Du gène au comportement : nouveau cheminement en direction de nouveaux agents psychotropes |
001413 |
P. Emond [France] ; L. Farde [Suède] ; S. Chalon [France] ; C. Belzung [France] ; V. Mauclaire [France] ; J. P. Chiron [France] ; C. Halldin [Suède] ; C. Besnard [France] ; D. Guilloteau [France] | Toxicity, mutagenicity, and behavioral effects of β-CIT, a ligand for dopamine transporter exploration by SPECT |
001428 |
A. Boireau [France] ; M. Meunier [France] ; A. Imperato [France] | Ouabain-induced increase in dopamine release from mouse striatal slices is antagonized by riluzole |
001434 |
F. Macar [France] | Neural bases of internal timers : A brief overview |
001440 |
B. Pillon [France] ; B. Deweer [France] ; M. Vidailhet [France] ; A.-M. Bonnet [France] ; V. Hahn-Barma [France] ; B. Dubois [France] | Is impaired memory for spatial location in Parkinson's disease domain specific or dependent on 'strategic' processes? |
001451 |
M. Gentil [France] ; C.-L. Tournier [France] ; S. Perrin [France] ; P. Pollak [France] | Effects of levodopa on finger and orofacial movements in Parkinson's disease |
001453 |
P. Morel [France] ; C. Tallineau [France] ; R. Pontcharraud [France] ; A. Piriou [France] ; F. Huguet [France] | Effects of 4-hydroxynonenal, a lipid peroxidation product, on dopamine transport and Na+/K+ ATPase in rat striatal synaptosomes |
001467 |
N. Aubin [France] ; O. Curet [France] ; A. Deffois [France] ; C. Carter [France] | Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice |
001472 |
| MECANISMES FONCTIONNELS ET NEURONAUX DES REGULATIONS TEMPORELLES CHEZ L'HOMME : NOYAUX GRIS CENTRAUX ET CERVELET |
001476 |
| Synthèse de Complexants Spécifiques de Catécholamines |
001477 |
| Développement de médicaments radiopharmaceutiques émetteurs de rayonnements gamma pour l'exploration du transporteur de la dopamine dans le système nerveux central |
001481 |
| CONTROLE DOPAMINERGIQUE DU NOYAU SYBTHALAMIQUE CHEZ LE RAT NORMAL ET CHEZ LE RAT MODELE DE LA MALADIE DE PARKINSON (RATS 6-OHDA) |
001487 |
D. Ho [États-Unis] ; R. Sapolsky [États-Unis] | Thérapie génique et système nerveux |
001548 |
A. Boireau [France] ; F. Bordier [France] ; P. Dubedat [France] ; C. Peny [France] ; A. Imperato [France] | Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice |
001564 |
B. Pillon [France] ; S. Ertle [France] ; B. Deweer [France] ; A.-M. Bonnet [France] ; M. Vidailhet [France] ; B. Dubois [France] | Memory for spatial location in 'de novo' parkinsonian patients |
001566 |
F. Huguet [France] ; G. Page [France] ; P. Morel [France] ; C. Tallineau [France] ; A. Piriou [France] | MPTP toxicity in rat striatal slices : dopamine uptake alteration does not appear to be related to lipid peroxidation |
001576 |
J. L. Montastruc [France] ; O. Rascol [France] ; J. M. Senard [France] | Glutamate antagonists and Parkinson's disease : A review of clinical data |
001579 |
V. Plante-Bordeneuve [France] ; D. Taussig [France] ; F. Thomas [France] ; G. Said [France] ; N. W. Wood [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; A. E. Harding [Royaume-Uni] | Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease : Evidence for association of a DRD2 allele |
001602 |
| Un organe de contrôle inspiré de la neuromodulation pour les Réseaux à Propagation Guidée |
001608 |
| SYSTEME DOPAMINERGIQUE NIGRO-STRIATAL : Etude des récepteurs D1 et des transporteurs de l'amine |
001635 |
E. Neuman [France] ; G. Rancurel [France] ; Y. Lecrubier [France] ; D. Fohanno [France] ; F. Boller [France] | Schizophreniform catatonia on 6 cases secondary to hydrocephalus with subthalamic mesencephalic tumor associated with hypodopaminergia |
001641 |
P. Barneoud [France] ; M. Mazadier [France] ; J.-M. Miquet [France] ; S. Parmentier [France] ; P. Dubedat [France] ; A. Doble [France] ; A. Boireau [France] | Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat |
001648 |
A. Mouatt-Prigent [France] ; J. O. Karlsson ; Yves Agid [France] ; E. C. Hirsch [France] | Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon : A role in nerve cell death ? |
001654 |
M. T. Herrero [Espagne] ; S. J. Augood [Royaume-Uni] ; H. Asensi [Espagne] ; E. C. Hirsch [France] ; Yves Agid [France] ; J. A. Obeso [Espagne] ; P. C. Emson [Royaume-Uni] | Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys |
001655 |
C. Adelbrecht [France] ; Yves Agid [France] ; R. Raisman-Vozari [France] | Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area |
001672 |
M.-E. Llau [France] ; G. Durrieu [France] ; M.-A. Tran [France] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France] | A study of dopaminergic sensitivity in Parkinson's disease : Comparison in ''de novo'' and levodopa-treated patients |
001673 |
| Etude de la plasticité des neurones dopaminergiques du mésencéphale ventral dans un modèle expérimental de la phase préclinique de la maladie de Parkinson: adaptations à long terme de la tyrosine hydroxylase et des transporteurs de la dopamine |
001675 |
| Acides amines excitateurs et dopamine au niveau des ganglions de la base: contribution à la réalisation d'une tâche motrice conditionnée chez le rat |
001679 |
| Synthèse et marquage au carbone-11 et au fluor-18 d'inhibiteurs de capture de la Dopamine pour une étude du système dopaminergique en Tomographie par Emission de Positons |
001691 |
F. Thibaut [France] ; J. M. Vaugeois [France] ; M. Petit [France] | Le transporteur de la dopamine : caractérisation et implications physiopathologiques |
001694 |
J. Costentin [France] | La maladie de Parkinson et le complexe de capture neuronal de la dopamine |
001714 |
R.-M. Marie ; L. Barre [France] ; P. Rioux ; P. Allain [France] ; B. Lechevalier ; J.-C. Baron | PET imaging of neocortical monoaminergic terminals in Parkinson's disease |
001720 |
A. Boireau [France] ; F. Bordier ; P. Dubedat ; A. Doble | Methamphetamine and dopamine neurotoxicity : differential effects of agents interfering with glutamatergic transmission |
001722 |
V. Blanchard [France] ; M. Chritin ; SHEELA VYAS [France] ; M. Savasta ; C. Feuerstein ; Yves Agid [France] ; F. Javoy-Agid [France] ; R. Raisman-Vozari [France] | Long-term induction of tyrosine hydroxylase expression : compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain |
001728 |
P. Barneoud [France] ; S. Parmentier ; M. Mazadier ; J. M. Miquet ; A. Boireau ; P. Dubedat ; J.-C. Blanchard | Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat |
001742 |
B. Naudin [France] ; J.-J. Bonnet ; J. Costentin | Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice |
001745 |
A. M. Bonnet [France] ; I. Serre [France] ; R. Marconi [France] ; Yves Agid [France] ; B. Dubois [France] | A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine |
001753 |
| Effets neurotoxiques induits par des radicaux libres sur le système dopaminergique nigro-striatal. Etude d'agents protecteurs |
001786 |
A. Boireau [France] ; J.-M. Miquet ; P. Dubedat ; M. Meunier ; A. Doble | Riluzole and experimental parkinsonism : partial antagonism of MPP+-induced increase in striatal extracellular dopamine in rats in vivo |
001787 |
A. Boireau [France] ; P. Dubedat ; F. Bordier ; C. Peny ; J.-M. Miquet ; G. Durand ; M. Meunier ; A. Doble | Riluzole and experimental parkinsonism : antagonism of MPTP-induced decrease in central dopamine levels in mice |
001794 |
S. Lehericy [France] ; J.-P. Brandel [France] ; E. C. Hirsch [France] ; P. Anglade [France] ; J. Villares [France] ; D. Scherman [France] ; C. Duyckaerts [France] ; F. Javoy-Agid [France] ; Yves Agid [France] | Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography |
001799 |
C. Malapani [France] ; B. Pillon ; B. Dubois ; Yves Agid [France] | Impaired simultaneous cognitive task performance in Parkinson's disease : a dopamine-related dysfunction |
001818 |
| Caractérisation moléculaire de récepteurs dopaminergiques murins de sous-type D2 et de leur mécanisme de transduction du signal |
001858 |
J. Nguyen-Legros [France] ; C. Harnois ; T. Di Paolo ; A. Simon [France] | The retinal dopamine system in Parkinson's disease |
001859 |
I. Marey-Semper [France] ; M. Gelman ; M. Levi-Strauss | The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra |
001886 |
G. Masson [France] ; D. Mestre ; O. Blin | Dopaminergic modulation of visual sensitivity in man |
001940 |
P. Pollak [France] ; C. L. Gervason ; D. Deffond ; J. E. Perret | Apomorphine et maladie de Parkinson : un progrès thérapeutique majeur |
001958 |
E. C. Hirsch [France] ; A. Mouatt ; B. Faucheux ; A.-M. Bonnet ; F. Javoy-Agid ; A. M. Graybiel ; Yves Agid [France] | Dopamine, tremor, and Parkison's disease |
001A11 |
M. Mavridis [France] ; A.-D. Degryse ; A. J. Lategan ; M. R. Marien ; F. C. Colpaert | Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tretrahydropyridine in monkeys : a possible role for the locus coeruleus in the progression of Parkinson's disease |
001A94 |
G. Renoux ; K. Biziere ; M. Renoux ; R. Steinberg ; J.-P. Kan ; J.-M. Guillaumin | Sodium diethyldithiocarbamate protects against the MPTP-induced inhibition of immune responses in mice |
001B29 |
L. Pierot ; C. Desnos ; J. Blin ; R. Raisman ; D. Scherman ; F. Javoy-Agid ; M. Ruberg ; Yves Agid [France] | D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy |
001B55 |
R. Cash ; T. Dennis ; R. L'Heureux ; R. Raisman ; F. Javoy-Agid ; B. Scatton | Parkinsons disease and dementia: norepinephrine and dopamine in locus ceruleus |
001C01 |
B. Bokobza ; M. Ruberg ; B. Scatton ; F. Javoy-Agid ; Yves Agid [France] | [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy |